April 13,2010 - Pancreatic Enzyme Therapy Approved by FDA to Treat Exocrine Pancreatic Insufficiency - Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) announced that the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for PANCREAZE™ (pancrelipase) delayed-release capsules for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Exocrine pancreatic insufficiency is the inability to properly digest and absorb food due to a lack of enzymes made by the pancreas that are important in the digestion of fats, proteins, and sugars... Johnson & Johnson's Press Release -
Apr 30, 2010
Johnson & Johnson Pharmaceutical Research and Development : FDA Approves New Drug Application for PANCREAZE
April 13,2010 - Pancreatic Enzyme Therapy Approved by FDA to Treat Exocrine Pancreatic Insufficiency - Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) announced that the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for PANCREAZE™ (pancrelipase) delayed-release capsules for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Exocrine pancreatic insufficiency is the inability to properly digest and absorb food due to a lack of enzymes made by the pancreas that are important in the digestion of fats, proteins, and sugars... Johnson & Johnson's Press Release -
